Last edition
News about "Radiation and Nuclear Countermeasures Program"
AFRRI to Evaluate Entolimod for Gastrointestinal Acute Radiation Syndrome
Valion Bio advances Entolimod to therapeutic efficacy testing at AFRRI, with an NIAID-funded study evaluating its potential to improve survival following radiation exposure.
Radiation And Nuclear Countermeasures Program | 03/11/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members